No Hepatitis After Treatment with a Modified Factor IX Concentrate in Previously Untreated Hemophiliacs
Authors: Pier Mannuccio Mannucci, Massimo Morfini, Loredana Gatti, Daniela Rafanelli, Massimo Colombo, Dario Geroldi, Monica Einarsson, Alessandro R. Zanetti
Journal: Annals of Internal Medicine (1985)

Brief Reports1 August 1985No Hepatitis After Treatment with a Modified Factor IX Concentrate in Previously Untreated HemophiliacsPIER MANNUCCIO MANNUCCI, M. D., MASSIMO MORFINI, M.D., LOREDANA GATTI, M.D., DANIELA RAFANELLI, M.D., MASSIMO COLOMBO, M.D., DARIO GEROLDI, M.D., MONICA EINARSSON, Ph.D., ALESSANDRO R. ZANETTI, Ph.D.PIER MANNUCCIO MANNUCCI, M. D.Search for more papers by this author, MASSIMO MORFINI, M.D.Search for more papers by this author, LOREDANA GATTI, M.D.Search for more papers by this author, DANIELA RAFANELLI, M.D.Search for more papers by this author, MASSIMO COLOMBO, M.D.Search for more papers by this author, DARIO GEROLDI, M.D.Search for more papers by this author, MONICA EINARSSON, Ph.D.Search for more papers by this author, ALESSANDRO R. ZANETTI, Ph.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-103-2-226 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPost-transfusion hepatitis is a serious and frequent complication in patients treated with clotting factor concentrates made from plasma pooled from a large number of donors. The occurrence is close to 100% in hemophiliacs who have not previously received blood or blood derivatives (first-exposure patients) (1-3). Recently, several manufacturers of concentrate have developed physical or chemical methods that remove or inactivate viruses with little or no loss of clotting factor activity. One manufacturer has added hydrophobic interaction chromatography on octanohydrazide-agarose to the regular fractionation process of a commercial concentrate of clotting factors II, VII, IX, and X (4). In-vitro studies have...References1. KASPERKIPNIS CS. Hepatitis and clotting factor concentrates [Letter]. JAMA. 1972;221:510. CrossrefMedlineGoogle Scholar2. FLETCHERTROWELLCRASKEPAVIERRIZZA MJJKC. Non-A, non-B hepatitis after transfusion of factor VIII in infrequently treated patients. Br Med J 1983;287:1754-7. CrossrefMedlineGoogle Scholar3. KERNOFFLEEKARAYIANNISTHOMAS PCPH. High risk of non-A, non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effect of prophylactic immune serum globulin. Br J Haematol. 1985;60:469-79. CrossrefMedlineGoogle Scholar4. EINARSSONKAPLANNORDENFELTMILLER MLEE. Removal of hepatitis B virus from a concentrate of coagulation factors II, VII, IX and X by hydrophobic interaction chromatography. J Virol Methods. 1981;3:213-28. CrossrefMedlineGoogle Scholar5. EINARSSONPRINCEBROTMAN MAB. Removal of non-A non-B hepatitis from a concentrate of the coagulation factors II, VII, IX and X by hydrophobic interaction chromatography. Scand J Infect Dis. 1985;17:141-6. CrossrefMedlineGoogle Scholar6. IWARSONKJELLMANTEGER-NILSSON SHA. Incidence of viral hepatitis after administration of factor IX concentrates. Vox Sang. 1976;31:136-40. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: PIER MANNUCCIO MANNUCCI, M. D.; MASSIMO MORFINI, M.D.; LOREDANA GATTI, M.D.; DANIELA RAFANELLI, M.D.; MASSIMO COLOMBO, M.D.; DARIO GEROLDI, M.D.; MONICA EINARSSON, Ph.D.; ALESSANDRO R. ZANETTI, Ph.D.Affiliations: Maggiore Hospital and University of Milan Milan ItalyHemophilia Center Florence ItalyUniversity of Pavia Pavia ItalyUniversity of Uppsala Uppsala Sweden PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPrevalence of Infection with the Hepatitis C Virus among Italian Hemophiliacs before and after the Introduction of Virally Inactivated Clotting Factor Concentrates: A Retrospective EvaluationPharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrateApproaches to the Reduction of Viral Infectivity in Cellular Blood Components and Single Donor PlasmaVirus inactivation in clotting factor concentrates: Facts and fanciesIn vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patientsVIRUCIDAL TREATMENT OF CLOTTING FACTOR CONCENTRATESWays to Reduce the Risk of Transmission of Viral Infections by Plasma and Plasma ProductsPharmakokinetische Untersuchungen an Hämophilie B-Patienten nach Infusion eines Faktor IX-KonzentratesFactor VIII Inhibitors.Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogsKlinische Studien zur Infektiosität von konventionellen und virusinaktivierten GerinnungsfaktorenkonzentratenHepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti-LAV/HTLV-III-positive patientsStudy Design: Two Standards?JOSEPH D. SAPIRA, M.D. 1 August 1985Volume 103, Issue 2Page: 226-227KeywordsBloodBlood plasmaChemical fractionationChromatographyHepatitis A ePublished: 1 December 2008 Issue Published: 1 August 1985 PDF downloadLoading ...